







Article

Cytokine Pattern of Peripheral Blood Mononuclear Cells Isolated from Children Affected by Generalized Epilepsy Treated with Different Protein Fractions of Meat Sources

Maria Giovanna Cilberti ¹, Antonella Santillo ^{1,*}, Anna N. Polito ², Giovanni Messina ³, Antonella della Malva ¹, Mariangela Caroprese ¹, Agostino Sevi ¹ and Marzia Albenzio ¹

¹ Department of Agriculture, Food, Natural Resources, and Engineering (DAFNE), University of Foggia, 71122 Foggia, Italy; maria.cilberti@unifg.it (M.G.C.); antonella.dellamalva@unifg.it (A.d.M.); mariangela.caroprese@unifg.it (M.C.); agostino.sevi@unifg.it (A.S.); marzia.albenzio@unifg.it (M.A.)

² Complex Structure of Neuropsychiatry Childhood-Adolescence of Ospedali Riuniti di Foggia, Viale Pinto, 71122 Foggia, Italy; annanupolito@gmail.com

³ Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; giovanni.messina@unifg.it

* Correspondence: antonella.santillo@unifg.it



Citation: Cilberti, M.G.; Santillo, A.; Polito, A.N.; Messina, G.; della Malva, A.; Caroprese, M.; Sevi, A.; Albenzio, M. Cytokine Pattern of Peripheral Blood Mononuclear Cells Isolated from Children Affected by Generalized Epilepsy Treated with Different Protein Fractions of Meat Sources. *Nutrients* **2022**, *14*, 2243. <https://doi.org/10.3390/nu14112243>

Academic Editors: José Joaquín Cerón, Alberto Muñoz-Prieto, Vladimir Mrljak and Lorena Franco-Martinez

Received: 22 April 2022

Accepted: 25 May 2022

Published: 27 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The objective of the present study was the evaluation of cytokine patterns in terms of TNF- α , IL-10, IL-6, and IL-1 β secretion in peripheral blood mononuclear cell (PBMC) supernatants isolated from blood of children affected by generalized epilepsy and treated in vitro with myofibrillar, sarcoplasmic, and total protein fractions of meat and fish sources. Children with generalized epilepsy (EC group, $n = 16$) and children without any clinical signs of disease, representing a control group (CC group $n = 16$), were recruited at the Complex Structure of Neuropsychiatry Childhood-Adolescence of Policlinico Riuniti (Foggia, Italy). Myofibrillar (MYO), sarcoplasmic (SA), and total (TOT) protein fractions were obtained from *longissimus thoracis* muscle of beef (BF) and lamb (LA); from *pectoralis* muscle of chicken (CH); and from dorsal white muscle of sole (*Solea solea*, SO), European hake (*Merluccius merluccius*, EH), and sea bass fish (*Dicentrarchus labrax*, SB), respectively. PBMCs were isolated from peripheral blood of EC and CC groups, and an in vitro stimulation in the presence of 100 $\mu\text{g}/\text{mL}$ for each protein fraction from different meat sources was performed. Data were classified according to three different levels of cytokines produced from the EC group relative to the CC group. TNF- α , IL-10, and IL-6 levels were not affected by different meat fractions and meat sources; on the contrary, IL-1 β levels were found to be significantly affected by the tested proteins fractions, as well as different meat sources, in high-level cytokine group. On average, the protein fractions obtained from LB, BF, and CH meat sources showed a higher level of IL-1 β than the protein fractions obtained from EH and SB fish samples. When all cytokine classes were analyzed, on average, a significant effect was observed for IL-10, IL-1 β , and TNF- α . Data obtained in the present study evidence that the nutritional strategy based on protein from fish and meat sources may modulate the immunological cytokine pattern of infants with generalized epilepsy.

Keywords: epilepsy; fish; meat; proteins; cytokines; inflammation

1. Introduction

Epilepsy represents a neurological disease with an incidence rate of 33/100,000–82/100,000 cases per year and affects the development of children, as well as their quality of life [1]. Epilepsy can be classified into focal epilepsy, generalized epilepsy, combined generalized, and unknown according to the standards of the International League against Epilepsy (ILAE). Several antiepileptic drugs (AEDs) have been recently used for epilepsy treatment; however, 20–30% of patients are found to be AED-resistant [2]. Due to the crucial role of diet in regulating inflammatory status and intestinal microbiota composition, nutritional strategies have gained interest in epilepsy research. A ketogenic diet is

considered a valid therapeutic strategy to treat children with intractable epilepsy, reducing inflammation at the intestinal level and preserving the homeostasis of the intestinal microbiome [3]. Whereas the mechanisms of action of a ketogenic diet related to seizure control are still being actively investigated, many theories have been proposed in this regard. One possible mechanism of action of a ketogenic diet is the neuroprotective effect of reducing oxidative stress at the mitochondrial level via ketone and polyunsaturated fatty acid (PUFA) production [4]. However, a ketogenic diet, in relation to low-protein consumption, may result in limitation of the levels of essential amino acids, which must be provided in the diet and include isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine [5]. Histidine amino acids are considered essential for the first year of life, and a deficiency of threonine, isoleucine, and histidine has been found to exacerbate seizures in rats [6]. Furthermore, the limitation of essential amino acids can excite a zone of high epileptogenicity contained in the anterior piriform cortex of the brain [7]. Overall, nutritional factors can play an important role in the regulation of electrical activity in the brain; thus, a deficiency of thiamine, pyridoxine, vitamin D, calcium, magnesium, and carnitine may be a cause of seizures. A subnormal concentration of these nutrients has been observed in most patients with epilepsy [8].

The inflammatory processes exert a crucial role in facilitating the development of epilepsy, and, in turn, epileptic seizures can trigger an inflammatory response [9], as supported by experimental and clinical findings [10]. Cytokines are able to correlate the central nervous system (CNS) and immune system in a bidirectional mode [11], mediating the development and regulation of the inflammatory and immune responses. Proinflammatory cytokines have been found to increase after single generalized or prolonged seizures [12]; thus, both the interleukin-1 receptor antagonist (IL-1Ra) and IL-6 have demonstrated neuroprotective and anticonvulsive effects during status epilepticus [13,14]. Based on previous statements, the relevance of the role of peripheral blood mononuclear cells (PBMC) is related to recent research on the pathogenesis of epilepsy with the aim of exploring the mechanisms mediating peripheral-to-central cell infiltration in both human and mouse models [15].

The effect of diet on the modulation of the gut–brain axis, brain inflammatory reactions, and dietary allergic disorders in epilepsy have been recently reviewed in childhood epilepsy [16]. The effects of protein fractions on human health have gained attention for their important role in stimulating innate immune response and activating pro- and anti-inflammatory cytokine release at a systemic level [17]. Milk protein fraction is a very heterogeneous nutritional component that impacts human health, and the related milk genetic polymorphism could play a role in the level and type of protein and derived peptides able to influence the *in vitro* cytokine pattern in epileptic infants [18]. Therefore, it could be of interest to explore the immunomodulatory role of protein from different animal protein food sources.

Our hypothesis is that protein fractions extracted from different meat and fish sources could have a potential immunomodulatory or stimulatory effect on cytokine patterns of infants with generalized epilepsy. The aim of this study was the investigation of TNF- α , IL-10, IL-6, and IL-1 β cytokines secretion in PBMC supernatants isolated from children affected by generalized epilepsy and treated *in vitro* with myofibrillar, sarcoplasmic, and total protein fractions of meat and fish sources.

2. Material and Methods

2.1. Patient Recruitment Procedure

Children with generalized epilepsy (epilepsy group (EC): 8 males, 8 females; mean age, 32.4 ± 4.4 mo) and children without any clinical signs of diseases (control group (CC): 8 male, 8 female; mean age, 33.6 ± 5.8 mo) were recruited at the Complex Structure of Neuropsychiatry Childhood-Adolescence of Policlinico Riuniti (Foggia, Italy). The principal biochemical and anthropometric characteristics are reported in Table 1. The patient inclusion and exclusion criteria were determined with reference to the work of

Albenzio et al. [19], and patients were treated with antiepileptic drugs (sodium valproate, 20 mg/kg/die). The study was approved by the local Ethics Committee on 22 May 2018, n°440/DS, the study was conducted according to the ethical principles of the Declaration of Helsinki, and written informed consent was obtained from the patients' parents.

Table 1. Main anthropometric and biochemical characteristics of children with generalized epilepsy (EC) and control children (CC) recruited for the study.

	EC	CC	p-Value
M/F	8/8	8/8	ns
AGE (MO)	32.4 ± 4.4	33.6 ± 5.8	ns
PERCENTILE	25°	25°	ns
GLYCEMIA (MG/DL)	75.5 ± 2.8	79.8 ± 3.6	ns
HEMOGLOBIN (G/DL)	12.9 ± 2.3	11.9 ± 1.2	ns
TOTAL CHOLESTEROL (MG/DL)	110 ± 5.6	115 ± 3.4	ns
TRIGLYCERIDES (MG/DL)	90.6 ± 6.1	109.7 ± 4.3	ns
ALBUMIN (G/DL)	3.5 ± 0.8	4 ± 2.1	ns
CRP (MG/DL)	<0.6	<0.6	ns

NS = not significant, M/F = Males/Females, CRP = C-Reactive Protein, p-value > 0.05.

2.2. Separation of Meat and Fish Proteins

Meat and fish samples were obtained from *longissimus thoracis* muscle for beef (BF) and lamb (LA); from *pectoralis* muscle for chicken (CH); and from dorsal white muscle for sole (*Solea solea*, SO), European hake (*Merluccius merluccius*, EH), and sea bass fish (*Dicentrarchus labrax*, SB), respectively. The separation of the two main meat and fish proteins fractions, myofibrillar (MYO) and sarcoplasmic (SA) proteins, was carried out following the method reported by della Malva et al. [20]. Briefly, meat samples were suspended in phosphate buffer (0.03 M, pH 7) containing a protease inhibitor cocktail (P2714, Sigma-Aldrich, St. Louis, MO, USA) and homogenized on ice for 2 min using an Ultra-Turrax T18 basic instrument (IKA, Wilmington, Germany). After centrifugation at 8000 × g for 20 min at 4 °C, the supernatant representing the sarcoplasmic protein fraction was collected, and the pellet was subsequently treated with a non-denaturing extraction method to extract myofibrillar proteins according to the protocol described by Hashimoto et al. [21], with some modifications as reported by della Malva et al. [20]. The non-denaturing extraction method was based on non-toxic and polluting agents; therefore, it resulted in a green solvent alternative method to mimic the effect of different protein fractions on peripheral mononuclear cells. Both myofibrillar and sarcoplasmic protein fractions were recovered into aqueous supernatant, then mixed (1:1) after protein concentration determination using a BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA) to obtain the total (TOT) protein fraction meat samples. On average, the TOT protein fraction concentrations for each sample were: 3571.76 µg/mL for lamb, 2743.08 µg/mL for European hake, 5082.06 µg/mL for chicken, 2749.01 µg/mL for sole, 2879.47 µg/mL for sea bass, and 5956.1 µg/mL for beef. All the meat and fish protein fractions (MYO, SAR, and TOT) were frozen at −80° for the lyophilization procedure.

2.3. SDS-PAGE Analysis of Fish and Meat Samples

Myofibrillar, sarcoplasmic, and total protein fractions from each meat source were resolved by SDS-polyacrylamide gel electrophoresis in an 8–18% gradient gel and analyzed according to method reported by della Malva et al. [20]. Gel was analyzed with Quantity One software Version 4.6.3 (Bio-Rad Laboratories, Hercules, CA, USA), and the respective protein molecular weight was obtained by comparison with precision plus protein standard-broad range (Bio-Rad Laboratories, Hercules, CA, USA).

2.4. Determination of Cytokine Profile from PBMCs Supernatants

The levels of TNF-α, IL-10, IL-6, and IL-1β cytokines secreted by PBMC supernatants were determined after incubation with 100 µg/mL of different meat protein fractions (SA,

MYO, and TOT) obtained from meat and fish species according to the protocol previously described by Albenzio et al. [16,19]. Peripheral blood was collected in heparinized tubes from EC and CC groups. The PBMC isolation procedure and protein fraction concentration used in in vitro the trial were chosen according to Albenzio et al. [19]. Briefly, PBMCs were isolated using Ficoll–Histopaque (Sigma Aldrich, Milan, Italy) density gradient centrifugation. All the proteins fractions were suspended into RPMI-1640 medium (Sigma Aldrich) supplemented with L-glutamine, penicillin/streptomycin, and 10% fetal bovine serum (Sigma Aldrich). A concentration of 1.5×10^5 cells/mL was seeded into sterile 96-well microtiter plates and activated with the mitogen phytohemagglutinin (PHA, 10 µg/mL), 100 µL of each protein fraction was added to each well, and the plates were cultured for 5 days in 5% CO₂ in a humidified incubator. PHA-activated PBMCs represented the positive control (PC), whereas PBMC with only culture medium was used as negative control (NC). All the treatments were tested in quadruplicate. PBMC viability after culturing time was determined using a trypan blue dye exclusion test and resulted in >90% viability. In vitro treatments were represented by PC, NC, SA-LA, MYO-LA, TOT-LA, SA-CH, MYO-CH, TOT-CH, SA-BF, MYO-BF, TOT-BF, SA-EH, MYO-EH, TOT-EH, SA-SO, MYO-SO, TOT-SO, SA-SB, MYO-SB, and TOT-SB. Cell-free supernatants were collected and immediately stored at -20 °C until cytokine profile determination using Luminex Multiplex assays (Thermo Fisher Scientific, Waltham, MA, USA).

2.5. Statistical Analysis

Data were tested for normal distribution using the Shapiro–Wilk test [22] and analyzed by ANOVA using the MIXED procedure of the SAS Institute (Cary, North Carolina, USA) [23]. The fixed effects were represented by meat proteins (sarcoplasmic fraction, myofibrillar fraction, and total protein fraction), meat sources (lamb, chicken, beef, European hake, sole, and sea bass), and their interactions. For cytokine response, patients were grouped according to Table 2, in which LL-EC represents the group of children with epilepsy with similar levels of cytokines to those of control children, ML-EC represents the group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children, and HL-EC represents the group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children. To clarify the role of different cytokine groups in in vitro responses, additional fixed effects were tested, including classes (LL-EC, ML-EC, and HL-EC), the in vitro treatment (CS, CN, and all meat proteins fractions and species), and their interactions. When significant effects were found (at $p < 0.05$), Tukey post hoc test for multiple comparisons was used to identify significant differences between means. $p = 0.10$ was considered a tendency.

Table 2. Percentage distribution of children with epilepsy grouped according to levels of different cytokines in peripheral blood mononuclear cell supernatants.

Cytokines	Class ¹		
	LL-EC	ML-EC	HL-EC
TNF- α	60	20	20
IL-6	60	20	20
IL-1 β	60	30	10
IL-10	70	20	10

¹ LL-EC = group of children with epilepsy with similar levels of cytokines to those of control children; ML-EC = group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children; HL-EC = group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children. TNF = Tumor necrosis factor, IL = Interleukin.

3. Results

3.1. Characterization of Proteomic Profile of Meat and Fish Extracts

The proteomic profiles of meat and fish (Figure 1a and Figure 1b, respectively) sources revealed that the main myofibrillar proteins were myosin heavy chain, α -actinin, desmin, actin, troponin T, tropomyosin, myosin light chain 1, and myosin light chain 2. Sarcoplasmic

proteins were mainly characterized by glycolytic enzymes, including glycogen phosphorylase b kinase, phosphoglucumutase, phosphoglucose isomerase, enolase, creatine kinase, glyceraldehyde phosphate dehydrogenase, phosphoglycerate mutase, and triosephosphate isomerase. However, all the species analyzed showed protein fragments in the molecular weight range of 180 to 110 KDa, mainly represented by the myosin heavy chain from 95 to 60 KDa, with the principal bands ascribed to α -actinin and phosphoglucumutase. In the lower part of the electrophoretogram, protein fragments derived from actinin, troponin T, glyceraldehyde, and myosin light-chain isoforms were detected.




Figure 1. Gradient (8–18%) SDS-PAGE gel of myofibrillar (MYO), sarcoplasmic (SAR), and total (TOT) protein fractions extracted from beef (BF), lamb (LA), and chicken (CH) meat samples (a); and sole (SO), European hake (EH), and sea bass fish (SB) meat sources (b). M1 = myosin heavy chain; M2 = α -actinin; M3 = desmin; M4 = actin; M5 = troponin T; M6 = tropomyosin; M7 = myosin light chain 1; M8 = myosin light chain 2; S1 = glycogen phosphorylase b kinase; S2 = phosphoglucumutase; S3 = phosphoglucose isomerase; S4 = enolase; S5 = creatine kinase; S6 = glyceraldehyde phosphate dehydrogenase; S7 = phosphoglycerate mutase; S8 = triosephosphate isomerase.

3.2. Cytokine Pattern

The cytokine pattern, in terms of TNF- α (Figure 2), IL-6 (Figure 3) and IL-10 (Figure 4), was not affected by different meat fractions and meat sources according to analysis of data within each class of cytokine response (LL-EC, ML-EC, and HL-EC).

On the contrary, IL-1 β in the HL-EC class showed a significant effect for the different protein fractions tested ($p = 0.004$), different meat sources ($p = 0.001$), and their interaction ($p = 0.001$). On average, MYO protein fractions had lower levels of IL-1 β than SAR protein fractions ($p = 0.003$). Additionally, protein fractions obtained from LB, BF, and CH meat

sources showed a higher level of IL-1 β than protein fractions obtained from EH and SB fish samples, on average. The interaction between different protein fractions and meat sources demonstrated that MYO-EH had the lowest level of IL-1 β (Figure 5). In order to facilitate the interpretation of results, Figures 2–5 show the interaction between the different meat fractions and meat sources in cytokine classes LL-EC, ML-EC, and HL-EC.




Figure 2. TNF- α secretion (means \pm SE; pg/mL) in peripheral blood mononuclear cell supernatants of infants with generalized epilepsy treated in vitro with myofibrillar (MYO, light-grey bar), sarcoplasmic (SA, grey bar), and total protein (TOT, black bar) fractions from beef (BF), lamb (LA), chicken (CH), sole (SO), European hake (EH), and sea bass (SB) sources. LL-EC = group of children with epilepsy with similar levels of cytokines to those of control children; ML-EC = group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children; HL-EC = group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children.




Figure 3. IL-6 secretion (means \pm SE; pg/mL) in peripheral blood mononuclear cell supernatants of infants with generalized epilepsy treated in vitro with myofibrillar (MYO, light-grey bar), sarcoplasmic (SA, grey bar), and total protein (TOT, black bar) fractions from beef (BF), lamb (LA), chicken (CH), sole (SO), European hake (EH), and sea bass (SB) sources. LL-EC = group of children with epilepsy with similar levels of cytokines to those of control children; ML-EC = group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children; HL-EC = group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children.




Figure 4. IL-10 secretion (means \pm SE; pg/mL) in peripheral blood mononuclear cell supernatants of infants with generalized epilepsy treated in vitro with myofibrillar (MYO, light-grey bar), sarcoplasmic (SA, grey bar), and total protein (TOT, black bar) fractions from beef (BF), lamb (LA), chicken (CH), sole (SO), European hake (EH), and sea bass (SB) sources. LL-EC = group of children with epilepsy with similar levels of cytokines to those of control children; ML-EC = group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children; HL-EC = group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children.




Figure 5. IL-1 β secretion (means \pm SE; pg/mL) in peripheral blood mononuclear cell supernatants of infants with generalized epilepsy treated in vitro with myofibrillar (MYO, light-grey bar), sarcoplasmic (SA, grey bar), and total protein (TOT, black bar) fractions from beef (BF), lamb (LA), chicken (CH), sole (SO), European hake (EH), and sea bass (SB) sources. LL-EC = group of children with epilepsy with similar levels of cytokines to those of control children; ML-EC = group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children; HL-EC = group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children. * $p < 0.05$.

Data were further analyzed, including the effects of the three cytokine classes, the in vitro treatments, and their interaction. Cytokine classes were found to significantly affect the cytokine pattern ($p < 0.001$ for all cytokines). Furthermore, with respect to the effect of all the in vitro treatments including SC and NC on the three cytokine classes was found to be significant, on average, for TNF- α ($p < 0.001$), IL-10 ($p = 0.01$), IL-1 β ($p < 0.001$), and as a tendency for IL-6 ($p = 0.06$) (Figure 6a–d). The interaction between the three cytokine classes and in vitro treatments was found to be significant for IL-10, IL-1 β , and TNF- α ($p < 0.001$). To simplify data presentation, the effects of all in vitro treatments are presented in Figure 6.

The IL-10 secretion of PC cells did not differ between MYO protein from LA and CH, and between SA protein from CH meat sources. However, MYO protein fractions from EH, SO, and BF sources; SA protein fractions from LA, EH, SO, and SB; and TOT proteins from all the meat sources showed significantly lower levels those of PC (Figure 6a). Regarding the level of IL-1 β , MYO protein fractions from EH and TOT, as well as protein fractions from SB meat sources, were reduced as compared to PC and all other meat protein fractions and sources (Figure 6b). On the contrary, TNF- α secretion did not differ between in vitro treatments, showing the lowest levels in NC PBMC, as expected (Figure 6c). Similar levels of IL-6 secretion were observed in PC in MYO protein fractions from SB meat sources and in SA protein fractions from EH, CH, and BF meat sources. All other in vitro treatments resulted in IL-6 levels comparable to those of NC PBMC (Figure 6d).




Figure 6. Cytokine pattern in terms of (a) TNF- α , (b) IL-10, (c) IL-1 β , and (d) IL-6 (means \pm SE; pg/mL) averaged among different classes (LL-EC = group of children with epilepsy with similar levels of cytokines to those of control children; ML-EC = group of children with epilepsy with cytokine levels at least 2-fold higher (medium levels) than those of control children; HL-EC = group of children with epilepsy with cytokine levels at least 8-fold higher (high levels) than those of control children) and based on in vitro treatments (NC = negative control, PC = positive control, SA-LA = sarcoplasmic protein fractions from lamb meat, MYO-LA = myofibrillar protein fraction from lamb meat, TOT-LA = total protein fractions from lamb meat, SA-CH = sarcoplasmic protein fractions from chicken meat, MYO-CH = myofibrillar protein fractions from chicken meat, TOT-CH = total protein fractions from chicken meat, SA-BF = sarcoplasmic protein fractions from beef, MYO-BF = myofibrillar protein fractions from beef, TOT-BF = total protein fractions from beef, SA-EH = sarcoplasmic protein fractions from European hake fish meat, MYO-EH = myofibrillar protein fractions from European hake fish meat, TOT-EH = total protein fractions from European hake fish meat, SA-SO = sarcoplasmic protein fractions from sole fish meat, MYO-SO = myofibrillar protein fractions from sole fish meat, TOT-SO = total protein fractions from sole fish meat, SA-SB = sarcoplasmic protein fractions from sea bass, MYO-SB = myofibrillar protein fractions from sea bass, and TOT-SB = total protein fractions from sea bass. ^{a-d} Means with different letters are significantly different, $p < 0.05$.

4. Discussion

The role of inflammation in epileptic seizure is the subject of debate; however, it has been confirmed that an inflammatory state is originated from seizure-induced damage to the brain and from excessive muscular activity [24]. Cytokines are inflammatory mediators that regulate cell growth, activation, and differentiation, as well as inflammatory response [25]. An emerging area of research focuses on determining the extent of involvement of peripheral immune cells in the inflammatory pathology of epilepsy [26].

Previous studies have demonstrated that protein fractions from bovine, caprine, and ovine milk can modulate the secretion of cytokines in *in vitro* PMBC isolated from infants with generalized epilepsy [19]. The differences in cytokine responses are associated with the genetic polymorphisms of milk proteins; β -CN fractions from ovine and caprine milk were found to induce the highest levels of TNF- α , whereas α S2- CN fractions from bovine milk were found to produce the highest levels of IL-6 play a major role in production of IL-1 β [27].

To the best of our knowledge, this is the first study in which the possible immunostimulatory or immunomodulatory role, in terms of cytokine pattern, of the main protein fractions extracted from different meat sources has been investigated in PBMCs of children with generalized epilepsy.

A multitude of scientific evidence of the immune-related compounds involved in epilepsy demonstrates that PBMCs from epilepsy patients after an *in vitro* challenge with different stimulators produce increased amounts of inflammatory mediators of the IL-1 family (IL-6, IL-10, and IFN- α) compared to PBMCs of control patients [28–33]. Therefore, if the immune-related cells of patients with epilepsy, upon stimulation, react with a “hyper-reactive immune state”. Accordingly, in the present study, the high reactive immune state of epileptic patients was discovered in ML-EC and HL-EC classes, although not all epileptic patients responded to mitogen stimulation at the same level for each cytokine. More than 50% of epileptic patients had similar cytokine levels to those of control patients. For TNF- α , IL-6, IL-1 β , and IL-10, at least 10% of epileptic patients was classified into the LL and HL classes.

Cytokine pattern has a relevant role in epileptic disorders; therefore, the use of cytokine inhibitors has been studied as a possible treatment for epilepsy in animal studies. It was found that a recombinant IL-1 receptor antagonist significantly reduced seizure duration and recurrence [34–36], as well as incidence of status epilepticus in rodents [37]. A possible upregulation or downregulation of proinflammatory cytokines, such as IL-6, IL-1 β , TNF- α ; as well as anti-inflammatory cytokines, such as IL-4, IL-6, IL-10, IL-11, and IL-13, can be mediated by nutraceutical which defined an immune-boosting property of such foods [38]. Nutritional treatment with low levels of proinflammatory nutrients and high levels of nutrients with anti-inflammatory properties may be conceived against autoimmune and other chronic diseases. Red meat has proinflammatory properties, as a dietary source of arachidonic acid, which plays a role in the production of proinflammatory eicosanoids [39]. In the present study, the proinflammatory IL-1 β in hyper-reactive immune-state patients (LL-EC) was decreased by MYO, SAR, and TOT protein fractions from European hake and sole fish meat sources. The reductive role of the pro-inflammatory IL-1 β of myofibrillar protein fraction from fish meat sources was confirmed by averaging cytokine classes. This clearly demonstrated that myofibrillar fractions from fish sources can exert an inflammation-modulatory role in PBMCs from patients with epilepsy, such as a model of systemic response. On the contrary, PBMCs from epileptic patients and in the presence of bovine whey protein fractions, as well as caprine milk and its casein fractions, induced the highest levels of IL-1 β in 60% and 80% of cases, respectively [27]. This finding is of relevance for the key role of the IL-1 β system and contributes to epileptic seizures and the possible effect diet mediation. Recently, novel targets for pharmacological intervention based on anti-IL-1 β treatments using small molecules or peptides have been experimentally investigated in clinical use for treatment of peripheral chronic inflammatory diseases [40]. In particular, the compromised blood–brain barrier (BBB) in epileptogenic brain tissue [41]

suggests that brain penetration of systemically delivered drugs is preferential in diseased tissue with ongoing proinflammatory processes [42–44]. Therefore, increases in several inflammatory mediators, including the IL-1 β and IL-1 receptor type 1 (IL-1R1), found in epileptogenic brain specimens in patients with drug-resistant epilepsy of different etiologies could be treated with IL-1-converting enzyme (ICE)/caspase 1 inhibitors and IL-1 β receptor antagonists [40].

Kim and Cho [45] summarized a selection of nutritional suggestions that have proven beneficial in treating different types of epilepsy; fundamental molecular mechanisms, followed by an introduction to several functional nutrients that have the potential to manage seizure frequencies, were ascribed to molecules as omega-3 PUFA, vitamin D3, vitamin E, vitamin B6, vitamin C, and pyruvate. In this context, beneficial effects may be addressed by animal-derived food products naturally enriched with bioactive and functional nutrients by means of husbandry strategies such as animal feed supplements or natural pasture [46]. Moreover, the introduction of a balanced amount of meat in the diet of children with generalized epilepsy treated with nutritional intervention could provide an adequate number of essential amino acids and fatty acids for growth and development and could help to control the activation of seizures mediated by severe deficiency of essential nutrients in the diet.

In a study of high-fat-fed rats, fish proteins were found to exert an anti-inflammatory effect by reducing TNF- α and IL-6 expression in visceral adipose tissue. Moreover, in LPS-treated macrophages, not all fish protein sources exerted anti-inflammatory actions via the same mechanism, which depended mainly to the model tested, such as adipose tissue [47]. Growing interest relies on the role of fish protein and the beneficial actions of fish consumption in glucose metabolism and inflammation, even if the related specific mechanisms remain unknown. One possible explanation for the beneficial properties of fish protein may be the combination of high proportions of certain amino acids, such as arginine and taurine, with low levels of branched-chain amino acids found in fish meat [47]. Furthermore, the demonstrated bioactive properties of fish proteins include the control of plasma cholesterol, lipoproteins, and triglycerides [48], as well as angiotensin-converting enzyme activity [49].

IL-10 is an anti-inflammatory cytokine known as a human cytokine synthesis inhibitor factor (CSIF) [50]. IL-10 was found to limit inflammation in the brain, and it accounts for the inhibition of the synthesis of proinflammatory agents, such as interferon-(IFN) γ , IL-2, IL-3, TNF- α , and granulocyte macrophage colony-stimulating factor (GM-CSF) [51]. In a prenatally stressed rat model of febrile seizures, the potential therapeutic effect of quercetin was studied, demonstrating that quercetin increased IL-10 levels, restoring them to the basal level found in non-stressed rats with febrile seizures by suppressing proinflammatory cytokines and suggesting its neuroprotective effect [52]. However, few studies have dealt with the alteration of IL-10 in epileptic patients; moreover, data from animal experiments revealed an enhancement of IL-10 serum levels in neonatal seizures induced by hypoxic-ischemic encephalopathy [53]; therefore, it may be useful as an antiseizure agent. On the contrary, no changes in plasma IL-10 were observed in children with febrile seizures [54]. Accordingly, in epileptic patients 72 h post seizure attack, peripheral IL-10 was not found to be different as compared with controls [55]. Moreover, in a study on postictal and interictal phases in active epilepsy patients, neither postictal nor interictal plasma IL-10 changed, suggesting that IL-10 may not exert antiseizure action during this period [56]. Cultured PBMCs from infants with generalized epilepsy in the presence of protein fractions from different milk sources resulted in an immunological state hypoactivated, with low levels of IL-10 detected in supernatants [27]. In PBMCs from infants with cow milk allergy and in the presence of bovine and caprine milk fractions, a high amount of IL-10 was detected as compared to healthy infants [17]. In the present experiment, myofibrillar protein from EH, SO, and BF sources; sarcoplasmic protein fractions from LA, EH, SO, and SB sources; and TOT protein from all meat sources were found to have a lower level of IL-10 than positive controls, demonstrating a potential inhibitory role of some proteins in the release of IL-10,

although no significant increment of IL-10 production was found any protein fractions in comparison to positive controls. This last concept can further explain the controversial contribution of IL-10 in the epilepsy.

Protein fractions from meat and fish can be considered a valid therapeutic strategy to treat children with epilepsy by reducing the inflammation state. Different protein fractions from meat and fish sources proved to be effective in the modulation of cytokines in our *ex vivo* study, suggesting that beneficial nutrients may be delivered in the diet with therapeutic efficacy to reducing seizures or, in some cases, to replace drugs in epileptic children.

5. Conclusions

Data obtained the present study demonstrate that protein extracts from different meat sources have a moderate effect on cytokine patterns of infants suffering from generalized epilepsy. Particularly evident was the modulatory role on the proinflammatory IL-1 β exerted by myofibrillar protein fractions extracted from fish sources. In addition, a slight anti-inflammatory effect on IL-10 production was demonstrated by myofibrillar and sarcoplasmic protein fractions from fish and meat sources, as well as all total protein fractions when analyzed in terms of averaged cytokine classes. Our findings present an opportunity to further validate nutritional interventions based on protein from animal sources to modulate the immunological cytokine pattern of infants with generalized epilepsy; however, further studies are needed to clarify the underlying specific molecular mechanism.

Author Contributions: Conceptualization, M.A., G.M. and A.S. (Antonella Santillo); methodology, M.G.C., A.d.M. and A.N.P.; data curation, M.G.C. and A.S. (Antonella Santillo); visualization, A.S. (Antonella Santillo), A.S. (Agostino Sevi), and M.C.; writing, M.G.C. and A.S. (Antonella Santillo); supervision, M.A. and G.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved by the local Ethics Committee on 22 May 2018, n°440/DS, and conducted according to the ethical principles of the Declaration of Helsinki.

Informed Consent Statement: Written informed consent was obtained from the patients' parents.

Data Availability Statement: All relevant data are presented within the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Plevin, D.; Smith, N. Assessment and management of depression and anxiety in children and adolescents with epilepsy. *Behav. Neurol.* **2019**, *2019*, 2571368. [[CrossRef](#)] [[PubMed](#)]
2. Chakraborty, A.R.; Almeida, N.C.; Prather, K.Y.; O'Neal, C.M.; Wells, A.A.; Chen, S.; Conner, A.K. Resting-state functional magnetic resonance imaging with independent component analysis for presurgical seizure onset zone localization: A systematic review and meta-analysis. *Epilepsia* **2020**, *61*, 1958–1968. [[CrossRef](#)] [[PubMed](#)]
3. Ciliberti, M.G.; Santillo, A.; Polito, R.; Messina, G.; Albenzio, M. *The Role of Milk Nutrition and Ketogenic Diet in Epileptic Disorders*; Exon Publications: Brisbane, Australia, 2022; ISBN 978-0-6453320-4-9. [[CrossRef](#)]
4. Ünalp, A. Ketogenic diet practices in childhood epilepsies. *İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi* **2017**, *7*, 169–177. [[CrossRef](#)]
5. Westmark, C.J. A role for amino acid balance in dietary treatments for epilepsy. *J. Nutr.* **2018**, *148*, 307–308. [[CrossRef](#)]
6. Gietzen, D.W.; Dixon, K.D.; Truong, B.G.; Jones, A.C.; Barrett, J.A.; Washburn, D.S. Indispensable amino acid deficiency and increased seizure susceptibility in rats. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **1996**, *271*, R18–R24. [[CrossRef](#)]
7. Rudell, J.B.; Rechs, A.J.; Kelman, T.J.; Ross-Inta, C.M.; Hao, S.; Gietzen, D.W. The anterior piriform cortex is sufficient for detecting depletion of an indispensable amino acid, showing independent cortical sensory function. *J. Neurosci.* **2011**, *31*, 1583–1590. [[CrossRef](#)]
8. Gaby, A.R. Natural approaches to epilepsy. *Altern. Med. Rev.* **2007**, *12*, 9.
9. Beghi, E.; Shorvon, S. Antiepileptic drugs and the immune system. *Epilepsia* **2011**, *52*, 40–44. [[CrossRef](#)]
10. Vezzani, A.; Granata, T. Brain inflammation in epilepsy: Experimental and clinical evidence. *Epilepsia* **2005**, *46*, 1724–1743. [[CrossRef](#)]
11. Muñoz-Fernández, M.; Fresno, M. The role of tumour necrosis factor, interleukin 6, interferon- γ and inducible nitric oxide synthase in the development and pathology of the nervous system. *Prog. Neurobiol.* **1998**, *56*, 307–340. [[CrossRef](#)]

12. Lehtimäki, K.A.; Keränen, T.; Palmio, J.; Mäkinen, R.; Hurme, M.; Honkaniemi, J.; Peltola, J. Increased plasma levels of cytokines after seizures in localization-related epilepsy. *Acta Neurol. Scand.* **2007**, *116*, 226–230. [[CrossRef](#)] [[PubMed](#)]
13. Vezzani, A.; Conti, M.; De Luigi, A.; Ravizza, T.; Moneta, D.; Marchesi, F.; De Simoni, M.G. Interleukin-1 β immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures. *J. Neurosci.* **1999**, *19*, 5054–5065. [[CrossRef](#)] [[PubMed](#)]
14. Penkowa, M.; Molinero, A.; Carrasco, J.; Hidalgo, J. Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures. *Neuroscience* **2001**, *102*, 805–818. [[CrossRef](#)]
15. Kamali, A.N.; Zian, Z.; Bautista, J.M.; Hamedifar, H.; Hossein-Khannazer, N.; Hosseinzadeh, R.; Yazdani, R.; Azizi, G. The potential role of pro-inflammatory and anti-inflammatory cytokines in epilepsy pathogenesis. *Endocr. Metab. Immune Disord.—Drug Targets* **2021**, *21*, 1760–1774. [[CrossRef](#)]
16. Albenzio, M.; Polito, A.N.; Santillo, A. The role of milk nutrition in childhood epilepsy. *Intern. J. Food Nutr. Sciences.* **2016**, *5*, 141–150.
17. Albenzio, M.; Campanozzi, A.; D’Apolito, M.; Santillo, A.; Mantovani, M.P.; Sevi, A. Differences in protein fraction from goat and cow milk and their role on cytokine production in children with cow’s milk protein allergy. *Small Rumin. Res.* **2012**, *105*, 202–205. [[CrossRef](#)]
18. Albenzio, M.; Santillo, A.; Caroprese, M.; Polito, A.N. Role of Milk from Small Ruminant Species on Human Health. In *Nutrients in Dairy and their Implications on Health and Disease*; Academic Press: Cambridge, MA, USA, 2017; pp. 435–440. [[CrossRef](#)]
19. Albenzio, M.; Santillo, A.; Ciliberti, M.G.; Figliola, L.; Caroprese, M.; Marino, R.; Polito, A. Milk from different species: Relationship between protein fractions and inflammatory response in infants affected by generalized epilepsy. *J. Dairy Sci.* **2016**, *99*, 5032–5038. [[CrossRef](#)]
20. Della Malva, A.; Albenzio, M.; Santillo, A.; Russo, D.; Figliola, L.; Caroprese, M.; Marino, R. Methods for extraction of muscle proteins from meat and fish using denaturing and nondenaturing solutions. *J. Food Qual.* **2018**, *2018*, 1–9. [[CrossRef](#)]
21. Hashimoto, K.; Watabe, S.; KoNo, M.; Shiro, K. Muscle protein composition of sardine and mackerel. *Bull. Jpn. Soc. Sci. Fish.* **1979**, *45*, 1435–1441. [[CrossRef](#)]
22. Shapiro, S.S.; Wilk, M.B. An Analysis of Variance Test for Normality (Complete Samples). *Biometrika* **1965**, *52*, 591–601. [[CrossRef](#)]
23. SAS Institute Inc. *SAS Enterprise Guide: Statistics*, Version 6.1 ed.; SAS Institute Inc.: Cary, NC, USA, 2013.
24. De Vries, E.E.; Van den Munckhof, B.; Braun, K.P.; Van Royen-Kerkhof, A.; De Jager, W.; Jansen, F.E. Inflammatory mediators in human epilepsy: A systematic review and meta-analysis. *Neurosci. Biobehav. Rev.* **2016**, *63*, 177–190. [[CrossRef](#)] [[PubMed](#)]
25. Yamanaka, G.; Takamatsu, T.; Morichi, S.; Yamazaki, T.; Mizoguchi, I.; Ohno, K.; Watanabe, Y.; Ishida, Y.; Oana, S.; Suzuki, S.; et al. Interleukin-1 β in peripheral monocytes is associated with seizure frequency in pediatric drug-resistant epilepsy. *J. Neuroimmunol.* **2021**, *352*, 577475. [[CrossRef](#)] [[PubMed](#)]
26. Commins, S.P.; Borish, L.; Steinke, J.W. Immunologic messenger molecules: Cytokines, interferons, and chemokines. *J. Allergy Clin. Immunol.* **2010**, *125*, S53–S72. [[CrossRef](#)] [[PubMed](#)]
27. Albenzio, M.; Santillo, A.; Ciliberti, M.G.; Figliola, L.; Caroprese, M.; Polito, A.; Messina, G. Milk nutrition and childhood epilepsy: An ex vivo study on cytokines and oxidative stress in response to milk protein fractions. *J. Dairy Sci.* **2018**, *101*, 4842–4852. [[CrossRef](#)] [[PubMed](#)]
28. Dunder, N.O.; Aktekin, B.; Ekinci, N.C.; Sahinturk, D.; Yavuzer, U.; Yegin, O.; Haspolat, S. Interleukin-1 β secretion in hippocampal sclerosis patients with mesial temporal lobe epilepsy. *Neurol. Int.* **2013**, *5*, 58–61. [[CrossRef](#)]
29. Helminen, M.; Vesikari, T. Increased Interleukin-1 (IL-1) Production from LPS-stimulated peripheral blood monocytes in children with febrile convulsions. *Acta Paediatr.* **1990**, *79*, 810–816. [[CrossRef](#)]
30. Matsuo, M.; Sasaki, K.; Ichimaru, T.; Nakazato, S.; Hamasaki, Y. Increased IL-1 β production from dsRNA-stimulated leukocytes in febrile seizures. *Pediatr. Neurol.* **2006**, *35*, 102–106. [[CrossRef](#)]
31. Nur, B.G.; Sahinturk, D.; Coskun, M.; Duman, O.; Yavuzer, U.; Haspolat, S. Single nucleotide polymorphism and production of IL-1 β and IL-10 cytokines in febrile seizures. *Neuropediatrics* **2012**, *43*, 194–200. [[CrossRef](#)]
32. Pacifici, R.; Paris, L.; Di Carlo, S.; Bacosi, A.; Pichini, S.; Zuccaro, P. Cytokine production in blood mononuclear cells from epileptic patients. *Epilepsia* **1995**, *36*, 384–387. [[CrossRef](#)]
33. Straussberg, R.; Amir, J.; Harel, L.; Punskey, I.; Bessler, H. Pro- and anti-inflammatory cytokines in children with febrile convulsions. *Pediatr. Neurol.* **2001**, *24*, 49–53. [[CrossRef](#)]
34. Librizzi, L.; Noè, F.; Vezzani, A.; De Curtis, M.; Ravizza, T. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. *Ann. Neurol.* **2012**, *72*, 82–90. [[CrossRef](#)] [[PubMed](#)]
35. Vezzani, A.; Moneta, D.; Richichi, C.; Aliprandi, M.; Burrows, S.J.; Ravizza, T.; Perego, C.; de Simoni, M.G. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. *Epilepsia* **2002**, *43*, 30–35. [[CrossRef](#)] [[PubMed](#)]
36. Vezzani, A.; Moneta, D.; Conti, M.; Richichi, C.; Ravizza, T.; De Luigi, A.; De Simoni, M.G.; Sperk, G.; Andell-Jonsson, S.; Lundkvist, J.; et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 11534–11539. [[CrossRef](#)] [[PubMed](#)]
37. Marchi, N.; Fan, Q.; Ghosh, C.; Fazio, V.; Bertolini, F.; Betto, G.; Batra, A.; Carlton, E.; Najm, I.; Granata, T.; et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. *Neurobiol. Dis.* **2009**, *33*, 171–181. [[CrossRef](#)] [[PubMed](#)]

38. Basak, S.; Gokhale, J. Immunity boosting nutraceuticals: Current trends and challenges. *J. Food Biochem.* **2021**, *46*, e13902. [[CrossRef](#)]
39. Francis, H.M.; Stevenson, R. Potential for diet to prevent and remediate cognitive deficits in neurological disorders. *Nutr. Rev.* **2018**, *76*, 204–217. [[CrossRef](#)]
40. Vezzani, A.; Balosso, S.; Maroso, M.; Zardoni, D.; Noé, F.; Ravizza, T. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. *Curr. Opin. Investig. Drugs* **2010**, *11*, 43–50.
41. Oby, E.; Janigro, D. The blood–brain barrier and epilepsy. *Epilepsia* **2006**, *47*, 1761–1774. [[CrossRef](#)]
42. Ravizza, T.; Gagliardi, B.; Noe', F.M.; Boer, K.; Aronica, E.; Vezzani, A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy. *Neurobiol. Dis.* **2008**, *29*, 142–160. [[CrossRef](#)]
43. Ravizza, T.; Boer, K.; Redeker, S.; Spliet, W.G.M.; Van Rijen, P.C.; Troost, D.; Vezzani, A.; Aronica, E. The IL-1 β system in epilepsy-associated malformations of cortical development. *Neurobiol. Dis.* **2006**, *24*, 128–143. [[CrossRef](#)]
44. Boer, K.; Jansen, F.; Nellist, M.; Van den Redeker, S.; Ouweland, A.M.W.; Spliet, W.G.M.; Van Nieuwenhuizen, O.; Troost, D.; Crino, P.B.; Aronica, E. Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. *Epilepsy Res.* **2008**, *78*, 7–21. [[CrossRef](#)] [[PubMed](#)]
45. Kim, J.-E.; Cho, K.-O. Functional nutrients for epilepsy. *Nutrients* **2019**, *11*, 130. [[CrossRef](#)] [[PubMed](#)]
46. Albenzio, M.; Santillo, A.; Avondo, M.; Nudda, A.; Chessa, S.; Pirisi, A.; Banni, S. Nutritional properties of small ruminant food products and their role on human health. *Small Rumin. Res.* **2015**, *135*, 3–12. [[CrossRef](#)]
47. Pilon, G.; Ruzzin, J.; Rioux, L.E.; Lavigne, C.; White, P.J.; Frøyland, H.J.; Bryle, P.; Beaulieu, L.; Marette, A. Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat–fed rats. *Metabolism* **2011**, *60*, 1122–1130. [[CrossRef](#)]
48. Demonty, I.; Deshaies, Y.; Jacques, H. Dietary proteins modulate the effects of fish oil on triglyceridemia in the rat. *Lipids* **1998**, *33*, 913–921. [[CrossRef](#)] [[PubMed](#)]
49. Pilon, G.; Dallaire, P.; Marette, A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: A new mechanism of action of insulin-sensitizing drugs. *J. Biol. Chem.* **2004**, *279*, 20767–20774. [[CrossRef](#)] [[PubMed](#)]
50. Levin, S.G.; Godukhin, O.V. Protective effects of interleukin-10 on the development of epileptiform activity evoked by transient episodes of hypoxia in rat hippocampal slices. *Neurosci. Behav. Physiol.* **2007**, *37*, 467–470. [[CrossRef](#)]
51. Opp, M.R.; Smith, E.M.; Hughes, T.K., Jr. Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep. *J. Neuroimmunol.* **1995**, *60*, 165–168. [[CrossRef](#)]
52. Mkhize, N.V.P.; Qulu, L.; Mabandla, M.V. The effect of quercetin on pro- and anti-inflammatory cytokines in a prenatally stressed rat model of febrile seizures. *J. Exp. Neurosci.* **2017**, *11*. [[CrossRef](#)]
53. Youn, Y.A.; Kim, S.J.; Sung, I.K.; Chung, S.Y.; Kim, Y.H.; Lee, I.G. Serial examination of serum IL-8, IL-10 and IL-1Ra levels is significant in neonatal seizures induced by hypoxic-ischaemic encephalopathy1. *Scand. J. Immunol.* **2012**, *76*, 286–293. [[CrossRef](#)]
54. Virta, M.; Hurme, M.; Helminen, M. Increased Plasma levels of pro- and anti-inflammatory cytokines in patients with febrile seizures. *Epilepsia* **2002**, *43*, 920–923. [[CrossRef](#)] [[PubMed](#)]
55. Mao, L.-Y.; Ding, J.; Peng, W.-F.; Ma, Y.; Zhang, Y.-H.; Fan, W.; Wang, X. Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients. *Epilepsia* **2013**, *54*, e142–e145. [[CrossRef](#)] [[PubMed](#)]
56. Gao, F.; Gao, Y.; Zhang, S.-J.; Zhe, X.; Meng, F.-L.; Qian, H.; Zhang, B.; Li, Y.-J. Alteration of plasma cytokines in patients with active epilepsy. *Acta Neurol. Scand.* **2017**, *135*, 663–669. [[CrossRef](#)] [[PubMed](#)]